These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7502038)

  • 1. Unraveling immune privilege.
    Streilein JW
    Science; 1995 Nov; 270(5239):1158-9. PubMed ID: 7502038
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunology and immunomodulation of corneal transplantation.
    Niederkorn JY
    Int Rev Immunol; 2002; 21(2-3):173-96. PubMed ID: 12424842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas ligand-induced apoptosis as a mechanism of immune privilege.
    Griffith TS; Brunner T; Fletcher SM; Green DR; Ferguson TA
    Science; 1995 Nov; 270(5239):1189-92. PubMed ID: 7502042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anterior chamber inoculation of splenocytes without Fas/Fas-ligand interaction primes for a delayed-type hypersensitivity response rather than inducing anterior chamber-associated immune deviation.
    Kawashima H; Yamagami S; Tsuru T; Gregerson DS
    Eur J Immunol; 1997 Oct; 27(10):2490-4. PubMed ID: 9368601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune privilege induced by cotransplantation of islet and allogeneic testicular cells.
    Lan P; Zhan W; Wang J; Yan L; Xiao L; Wu X
    Chin Med J (Engl); 2001 Oct; 114(10):1026-9. PubMed ID: 11677759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fas, fas ligand, immune tolerance, and cancer: implications in cancer of the colon].
    Berger A; Piqueras B; Pages F; Tartour E; Cugnenc PH; Fridman WH
    Bull Cancer; 1998 Feb; 85(2):129-33. PubMed ID: 9752329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testicular Sertoli cells exert both protective and destructive effects on syngeneic islet grafts in non-obese diabetic mice.
    Korbutt GS; Suarez-Pinzon WL; Power RF; Rajotte RV; Rabinovitch A
    Diabetologia; 2000 Apr; 43(4):474-80. PubMed ID: 10819241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anterior chamber-associated immune deviation.
    Niederkorn JY
    Chem Immunol; 1999; 73():59-71. PubMed ID: 10590574
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulation of Fas ligand-induced apoptosis by TNF.
    Elzey BD; Griffith TS; Herndon JM; Barreiro R; Tschopp J; Ferguson TA
    J Immunol; 2001 Sep; 167(6):3049-56. PubMed ID: 11544288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Die and let live: eliminating dangerous lymphocytes.
    Abbas AK
    Cell; 1996 Mar; 84(5):655-7. PubMed ID: 8625402
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors.
    Hori J; Kunishige T; Nakano Y
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunobiology and privilege of neuronal retina and pigment epithelium transplants.
    Streilein JW; Ma N; Wenkel H; Ng TF; Zamiri P
    Vision Res; 2002 Feb; 42(4):487-95. PubMed ID: 11853765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts.
    Tourneur L; Malassagne B; Batteux F; Fabre M; Mistou S; Lallemand E; Lores P; Chiocchia G
    J Immunol; 2001 Aug; 167(3):1338-46. PubMed ID: 11466351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye.
    Wang S; Boonman ZF; Li HC; He Y; Jager MJ; Toes RE; Niederkorn JY
    J Immunol; 2003 Sep; 171(6):2789-96. PubMed ID: 12960299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexity of the state of immunological tolerance.
    Hasek M; Chutná J
    Immunol Rev; 1979; 46():3-26. PubMed ID: 90009
    [No Abstract]   [Full Text] [Related]  

  • 17. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival.
    Min WP; Gorczynski R; Huang XY; Kushida M; Kim P; Obataki M; Lei J; Suri RM; Cattral MS
    J Immunol; 2000 Jan; 164(1):161-7. PubMed ID: 10605007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for CD95 ligand in preventing graft rejection.
    Bellgrau D; Gold D; Selawry H; Moore J; Franzusoff A; Duke RC
    Nature; 1995 Oct; 377(6550):630-2. PubMed ID: 7566174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy.
    Stein-Streilein J; Streilein JW
    Int Rev Immunol; 2002; 21(2-3):123-52. PubMed ID: 12424840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunoprotective effect of Sertoli cells coencapsulated with islet xenografts is not dependent upon Fas ligand expression.
    Yang H; Al-Jazaeri A; Wright JR
    Cell Transplant; 2002; 11(8):799-801. PubMed ID: 12588112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.